Viewing data from:

PEPTAVLON

NDA

PENTAGASTRIN | N017048 | WYETH AYERST LABORATORIES

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

1 petition from Regulations.gov

Petition	Type	Filed	Status	Petitioner
Citizen Petition from Arnall Golden Gregory LLP FDA-2005-P-0318 · 8 docket documents Arnall Golden Gregory LLP filed this citizen petition under section 505 of the Federal Food, Drug, and Cosmetic Act requesting that the FDA determine Wyeth Pharmaceuticals' Peptavlon (pentagastrin) for Subcutaneous Injection (NDA #17-048) was voluntarily withdrawn from sale for reasons other than sa	505(q)	2018-02-21	Granted	Arnall Golden Gregory LLP

Source: Regulations.gov. FDA citizen petitions matched by application number.

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Products (1)

#001 — 0.25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.